Candriam S.C.A. Sells 8,662 Shares of Medpace Holdings, Inc. $MEDP

Candriam S.C.A. lessened its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 14.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,655 shares of the company’s stock after selling 8,662 shares during the period. Candriam S.C.A.’s holdings in Medpace were worth $16,213,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of MEDP. Invesco Ltd. lifted its stake in Medpace by 9.4% in the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock valued at $361,596,000 after purchasing an additional 102,015 shares during the last quarter. Mawer Investment Management Ltd. increased its position in Medpace by 17.4% during the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after buying an additional 121,213 shares during the last quarter. AQR Capital Management LLC raised its stake in Medpace by 12.4% in the first quarter. AQR Capital Management LLC now owns 539,547 shares of the company’s stock valued at $158,470,000 after buying an additional 59,361 shares during the period. TD Asset Management Inc lifted its position in shares of Medpace by 15.6% in the second quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock valued at $143,636,000 after buying an additional 61,764 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Medpace by 36.0% in the first quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock valued at $102,830,000 after buying an additional 89,347 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft boosted their target price on Medpace from $270.00 to $430.00 and gave the stock a “hold” rating in a report on Wednesday, July 23rd. Rothschild Redb downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. William Blair restated a “market perform” rating on shares of Medpace in a research note on Wednesday, July 23rd. TD Cowen lifted their target price on shares of Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a report on Friday, October 24th. Finally, Barclays upped their price target on shares of Medpace from $425.00 to $485.00 and gave the company an “underweight” rating in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $487.18.

Insider Activity at Medpace

In related news, CEO August J. Troendle sold 36,196 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $475.90, for a total transaction of $17,225,676.40. Following the sale, the chief executive officer owned 925,799 shares of the company’s stock, valued at $440,587,744.10. This represents a 3.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Fred B. Davenport, Jr. sold 5,972 shares of Medpace stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $581.88, for a total value of $3,474,987.36. Following the completion of the transaction, the director directly owned 3,498 shares of the company’s stock, valued at $2,035,416.24. This represents a 63.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 134,211 shares of company stock valued at $74,459,958. 20.30% of the stock is currently owned by company insiders.

Medpace Stock Performance

MEDP opened at $591.32 on Friday. The stock has a fifty day moving average of $537.32 and a 200-day moving average of $420.81. The company has a market capitalization of $16.66 billion, a P/E ratio of 41.35, a P/E/G ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $625.00.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same period last year, the firm earned $3.01 earnings per share. Medpace’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.